Saluda Medical is a commercial-stage medical device company developing the Evoke System, the first physiologic closed-loop, dose-control spinal cord stimulation (SCS) system. The Evoke system senses and measures neural responses to stimulation and automatically adjusts therapy in real time. Founded in 2011 by John Parker in Australia, Saluda raised $100M in January 2025 led by Redmile Group and received FDA approval for EVA, its biomarker-based automated patient programming platform. A Lancet Neurology study showed 55% of Evoke patients reduced or eliminated opioid use after one year.